Key facts
- This page summarizes Ph.D. Alfred P. Spada's Form 3 filing for Histogen Inc..
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Feb 2023, 15:22.
Ph.D. Alfred P. Spada - 01 Feb 2023 Form 3 Insider Report for Histogen Inc.
- Reporting relationship
- Executive Vice President and Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Feb 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Feb 2023, 15:22:51 UTC
- Next SEC filing
- 27 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan A. Knudson as attorney-in-fact for Alfred P. Spada, Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Alfred P. Spada filed Form 3 for Histogen Inc. on 03 Feb 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HSTO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 979
- Date
- 01 Feb 2023
- Ownership
- Direct
HSTO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,235
- Date
- 01 Feb 2023
- Ownership
- See footnote
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Held by a family trust of which Dr. Spada is a trustee.
SEC remarks
Executive Vice President and Chief Scientific Officer